Here’s a startling fact: breast cancer isn’t just a statistic—it’s a reality knocking on our doors. But here’s where it gets controversial: despite its prevalence, we still don’t talk about it enough, and that silence is costing lives. Globally, 2.3 million women were diagnosed with breast cancer in 2022, and 670,000 lost their battle to it. In India, it’s now the most common cancer among women, yet too many are diagnosed only when it’s advanced. So, why does awareness matter? Let’s break it down.
First, early detection is a game-changer. When caught early, breast cancer treatments are far more effective, and survival rates soar. Second, awareness shatters the stigma and fear surrounding it. Many women ignore symptoms like lumps, nipple changes, or unusual discharge out of embarrassment or uncertainty. Third, knowing isn’t enough—action is key. While most have heard of breast cancer, few prioritize regular screenings or even know how to perform a self-check properly.
But there’s hope. And this is the part most people miss: advancements in testing and treatment are revolutionizing the fight against breast cancer. Beyond mammograms, we now have blood tests, genetic screenings, and advanced imaging that detect issues earlier than ever. Treatments, too, have evolved. Personalized medicine and targeted therapies allow doctors to tailor care to individual patients, moving beyond one-size-fits-all approaches.
A groundbreaking UK study from The Institute of Cancer Research, London, has introduced a blood test that predicts how advanced breast cancer patients will respond to therapy. Published in Clinical Cancer Research, the study focuses on circulating tumor DNA (ctDNA)—genetic material shed by cancer cells into the bloodstream. Researchers found a strong link between low ctDNA levels at the start of treatment and positive responses. Here’s the twist: while low ctDNA suggests a better prognosis, it’s not a guarantee. Some tumors shed minimal ctDNA, or the disease may hide in areas like the brain, making it undetectable. Dr. Arun Kumar Goel, Chairman of Surgical Oncology at Andromeda Cancer Hospital, explains, ‘ctDNA is a risk factor, not a definitive predictor.’
This test could reduce the need for invasive biopsies in certain cases, such as tracking treatment success or detecting resistance mutations. However, here’s the debate: can ctDNA testing fully replace biopsies? Dr. Goel clarifies, ‘While ctDNA is valuable, biopsies remain essential for initial diagnosis, tumor grading, and in-depth analysis.’*
So, what’s your take? Is ctDNA testing the future of cancer monitoring, or does it still have limitations? Share your thoughts in the comments—let’s keep the conversation going and break the silence around breast cancer.
